| 000 | 01843 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250515081314.0 | ||
| 264 | 0 | _c20071219 | |
| 008 | 200712s 0 0 eng d | ||
| 022 | _a0268-3369 | ||
| 024 | 7 |
_a10.1038/sj.bmt.1705801 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNakamura, R | |
| 245 | 0 | 0 |
_aReduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. _h[electronic resource] |
| 260 |
_bBone marrow transplantation _cNov 2007 |
||
| 300 |
_a843-50 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aGraft Survival |
| 650 | 0 | 4 | _aGraft vs Host Disease |
| 650 | 0 | 4 |
_aHematologic Diseases _xtherapy |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMelphalan _xtherapeutic use |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyelodysplastic Syndromes _xcomplications |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aTransplantation Conditioning _xmethods |
| 650 | 0 | 4 | _aTransplantation, Homologous |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVidarabine _xanalogs & derivatives |
| 700 | 1 | _aRodriguez, R | |
| 700 | 1 | _aPalmer, J | |
| 700 | 1 | _aStein, A | |
| 700 | 1 | _aNaing, A | |
| 700 | 1 | _aTsai, N | |
| 700 | 1 | _aChang, K | |
| 700 | 1 | _aSlovak, M L | |
| 700 | 1 | _aBhatia, R | |
| 700 | 1 | _aSpielberger, R | |
| 700 | 1 | _aKogut, N | |
| 700 | 1 | _aPullarkat, V | |
| 700 | 1 | _aKirschbaum, M | |
| 700 | 1 | _aForman, S J | |
| 700 | 1 | _aO'Donnell, M R | |
| 773 | 0 |
_tBone marrow transplantation _gvol. 40 _gno. 9 _gp. 843-50 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.bmt.1705801 _zAvailable from publisher's website |
| 999 |
_c17254445 _d17254445 |
||